Last reviewed · How we verify
Gadopentetate-Dimeglumine 0.05 mmol
Gadopentetate-Dimeglumine 0.05 mmol is a Gadolinium-based contrast agent Small molecule drug developed by Paracelsus Medical University. It is currently FDA-approved for MRI contrast enhancement for central nervous system imaging, MRI contrast enhancement for body imaging including cardiovascular and abdominal applications. Also known as: Magnevist.
Gadopentetate dimeglumine is a gadolinium-based contrast agent that accumulates in tissues and enhances magnetic resonance imaging (MRI) signal by shortening T1 relaxation time.
Gadopentetate dimeglumine is a gadolinium-based contrast agent that accumulates in tissues and enhances magnetic resonance imaging (MRI) signal by shortening T1 relaxation time. Used for MRI contrast enhancement for central nervous system imaging, MRI contrast enhancement for body imaging including cardiovascular and abdominal applications.
At a glance
| Generic name | Gadopentetate-Dimeglumine 0.05 mmol |
|---|---|
| Also known as | Magnevist |
| Sponsor | Paracelsus Medical University |
| Drug class | Gadolinium-based contrast agent |
| Target | Water protons (T1 relaxation enhancement) |
| Modality | Small molecule |
| Therapeutic area | Diagnostic Imaging |
| Phase | FDA-approved |
Mechanism of action
Gadopentetate dimeglumine is a paramagnetic gadolinium chelate complex that distributes in extracellular fluid and is taken up by tissues with increased vascularity or altered blood-brain barrier permeability. The gadolinium ion enhances MRI contrast by altering the relaxation properties of nearby water protons, improving visualization of anatomical structures and pathological lesions. The dimeglumine salt formulation improves solubility and safety by chelating the gadolinium ion.
Approved indications
- MRI contrast enhancement for central nervous system imaging
- MRI contrast enhancement for body imaging including cardiovascular and abdominal applications
Common side effects
- Gadolinium retention in tissues
- Nephrogenic systemic fibrosis (NSF) in patients with severe renal impairment
- Injection site reactions
- Headache
- Dizziness
Key clinical trials
- P03277 Dose Finding Study in Central Nervous System (CNS) Magnetic Resonance Imaging (MRI) (PHASE2)
- Retrospective Study of MRI With MULTIHANCE at 0.10 and 0.05 mmol/Kg Dose in CNS Patients
- Crossover Comparison of MultiHance and Dotarem (PHASE4)
- Contrast-enhanced MRI in Children 2 Months to <2 Years (PHASE3)
- Magnetic Resonance Imaging of Interscalene Plexus Block (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Gadopentetate-Dimeglumine 0.05 mmol CI brief — competitive landscape report
- Gadopentetate-Dimeglumine 0.05 mmol updates RSS · CI watch RSS
- Paracelsus Medical University portfolio CI
Frequently asked questions about Gadopentetate-Dimeglumine 0.05 mmol
What is Gadopentetate-Dimeglumine 0.05 mmol?
How does Gadopentetate-Dimeglumine 0.05 mmol work?
What is Gadopentetate-Dimeglumine 0.05 mmol used for?
Who makes Gadopentetate-Dimeglumine 0.05 mmol?
Is Gadopentetate-Dimeglumine 0.05 mmol also known as anything else?
What drug class is Gadopentetate-Dimeglumine 0.05 mmol in?
What development phase is Gadopentetate-Dimeglumine 0.05 mmol in?
What are the side effects of Gadopentetate-Dimeglumine 0.05 mmol?
What does Gadopentetate-Dimeglumine 0.05 mmol target?
Related
- Drug class: All Gadolinium-based contrast agent drugs
- Target: All drugs targeting Water protons (T1 relaxation enhancement)
- Manufacturer: Paracelsus Medical University — full pipeline
- Therapeutic area: All drugs in Diagnostic Imaging
- Indication: Drugs for MRI contrast enhancement for central nervous system imaging
- Indication: Drugs for MRI contrast enhancement for body imaging including cardiovascular and abdominal applications
- Also known as: Magnevist
- Compare: Gadopentetate-Dimeglumine 0.05 mmol vs similar drugs
- Pricing: Gadopentetate-Dimeglumine 0.05 mmol cost, discount & access